Loading
A phase 3 trial of Limertinib run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active.
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT04143607 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 337 participants enrolled, started 2019-07-23. Conditions listed: Locally Advanced or Metastatic NSCLC. No results are recorded here; the registry entry is the source.
Shares Limertinib, Aosaikang Pharmaceutical, Small-molecule kinase inhibitors, Non-small-cell lung cancer.